Jump to a section
- Research scope and peptide identity
- Mechanisms discussed in cited studies
- Study models and experimental designs
- Outcomes measured in the reviewed sources
- Reported study-design and protocol details
- Reported study-design details from cited sources
- Limitations and research gaps
- Documentation checklist
- Related research supplies
- More TB-500 research
- Sources and references
Disclosure: Peptide Bio Index is affiliated with SourcePoint Research and may earn from qualifying purchases or affiliate links.
This article summarizes published research and reported study designs. It is not medical advice, dosing guidance, or a personal-use recommendation.
Source-limited research note: The reviewed sources were incomplete, ambiguous, or insufficient for a normal article. This page labels missing details rather than guessing.
This overview summarizes reviewed literature on TB-500, a synthetic peptide fragment related to thymosin beta‑4 (Tβ4). It focuses on how the compound is described in identity/analytical reports, proposed mechanisms cited in reviews and experimental work, the preclinical study models used, endpoints measured, and explicit protocol details reported in the provided sources. Evidence is predominantly preclinical and analytical; clinical data are lacking in the reviewed material.
Research scope and peptide identity
TB-500 is described in analytical and experimental literature as a synthetic version of an active region of thymosin β4, corresponding to the peptide sequence LKKTETQ with N‑terminal acetylation reported for some preparations (Ac‑LKKTETQ); nomenclature in the literature alternates between TB‑500, thymosin beta‑4 fragment, and Tβ4-related terminology. [S8] [S4] [S7]
Reviews of therapeutic peptides and gerontology literature list TB‑500/Tβ4 among wound‑healing and tissue‑repair peptides evaluated across preclinical studies, while noting that clinical orthopaedic evidence is limited or absent. [S1] [S2] [S3] [S5]
Mechanisms discussed in cited studies
Preclinical and analytical sources attribute functions to the TB‑500/Tβ4 active region that include actin binding and promotion of cell migration, angiogenesis, keratinocyte migration, collagen deposition, and dermal wound healing; reviews place these activities in the broader context of extracellular matrix remodeling and fibroblast activation for tissue repair. [S8] [S4] [S1]
General peptide‑mechanism reviews referenced in the dataset identify molecular pathways commonly modulated by regenerative peptides (for example PI3K/Akt, mTOR, MAPK, TGF‑β, and AMPK), but direct mechanistic pathway interrogation specific to TB‑500 in the provided primary excerpts is limited. [S1]
Study models and experimental designs
Experimental approaches in the reviewed sources include in‑vitro assays (fibroblast wound‑healing assays and in‑vitro enzyme systems), analytical metabolism profiling in human serum, and animal studies in rats and horses (metabolism/detection in rat urine; Achilles tendon repair in rats; single‑dose administration and detection in horses). [S4] [S7] [S8]
Narrative reviews and safety/usage overviews synthesize these preclinical and analytical data but emphasize the predominance of non‑clinical evidence and the scarcity of controlled human orthopaedic trials. [S2] [S3]
Outcomes measured in the reviewed sources
Analytical/metabolism studies quantified TB‑500 and metabolites (for example Ac‑LK, Ac‑LKK, Ac‑LKKTE) using UHPLC‑Q‑Exactive orbitrap MS and assessed metabolite time courses (primary metabolite peak at 0–6 h; some metabolites detectable up to 72 h) and in‑vitro biological activity in fibroblast wound‑healing assays. [S4]
A controlled rat Achilles tendon repair study reported biomechanical testing (maximum load to failure), histopathological scoring (Bonar and Movin scores), histochemical staining (Masson trichrome, Sirius red birefringence), and immunohistochemical semiquantification of collagen types I and III as outcome measures. [S7]
Analytical doping‑control work in equine samples focused on detection and confirmation of N‑acetylated LKKTETQ and metabolites in plasma and urine using LC/MS, including reported detection limits in equine matrices. [S8] [S6]
Reviews note broader outcome domains addressed across the literature (tissue repair, angiogenesis, inflammation modulation), but emphasize that human clinical outcomes for orthopaedic indications are not established in the reviewed material. [S1] [S2] [S3]
Reported study-design and protocol details
Selected experimental and analytical protocol details explicitly reported in the reviewed sources include surgical tendon repair in rats with randomized group allocation and defined dosing regimens for the animal study, analytical detection methods and limits in equine and rat matrices, and in‑vitro wound‑healing and cytotoxicity assays used to compare parent peptide and metabolites. [S7] [S8] [S4]
Reported study-design details from cited sources
The following table summarizes protocol details reported in cited studies. These details are provided as literature context only and are not recommendations or instructions.
| Source | Study Type | Model / Subject | Amount Reported | Route Reported | Frequency | Duration | Notes |
|---|---|---|---|---|---|---|---|
| [S7] | animal (preclinical) – randomized surgical tendon repair study | male Sprague‑Dawley rats (12 weeks old, approximately 330 g) | TB-500 (synthetic thymosin beta-4) 60 µg/kg/day; BPC-157 10 µg/kg/day | intraperitoneal | daily | 4 weeks | Standardized Achilles tendon transection and repair; four groups (control, BPC‑157, TB‑500, BPC+TB), n=8 per group (total 32); endpoints at 4 weeks included biomechanical maximum load to failure, histopathology (Bonar, Movin), histochemistry, and immunohistochemistry. |
| [S4] | analytical/metabolism and in‑vitro biological activity study | human serum, various in‑vitro enzyme systems, fibroblast cell cultures, and rats (urine samples from treated animals) | not reported in the reviewed source | not reported in the reviewed source | not reported in the reviewed source | metabolite detection reported over a 0–72 hr window (primary metabolite highest at 0–6 hr; some metabolites detected up to 72 hr) | UHPLC‑Q‑Exactive orbitrap MS method developed/validated for simultaneous quantification of TB‑500 and metabolites; cytotoxicity assays reported no cytotoxicity; Ac‑LKKTE metabolite showed significant wound‑healing activity in fibroblasts compared to control. |
| [S8] | analytical/doping‑control detection in equine samples | horses (equine plasma and urine samples post‑administration) | single dose containing 10 mg N‑acetylated LKKTETQ (reported for administered preparation) | not reported in the reviewed source | single dose | not reported in the reviewed source | Solid‑phase extraction and LC/MS identification of parent and metabolites; reported confirmation limits of 0.02 ng/mL in plasma and 0.01 ng/mL in urine in equine matrices. |
Limitations and research gaps
- Evidence in the reviewed sources is predominantly preclinical and analytical; randomized controlled human orthopaedic or clinical trials are not reported in the provided excerpts.
- Mechanistic pathway data specific to TB‑500 are limited in the primary experimental excerpts; some mechanistic claims are extrapolated by reviews from broader peptide literature rather than directly demonstrated for TB‑500 in the supplied primary studies.
- Dosing, administration route, frequency, and long‑term safety data for human use are not provided in the reviewed sources.
Documentation checklist
- Confirm regulatory and anti‑doping status for TB‑500/Tβ4 in the relevant jurisdiction (e.g., WADA listings).
- Compare analytical methods and limits of detection when interpreting detection windows in different matrices (plasma vs urine).
- When reviewing experimental results, distinguish parent peptide activity from activity of identified metabolites (e.g., Ac‑LKKTE activity reported).
- Seek primary clinical trial data before extrapolating preclinical findings to human clinical outcomes.
Related research supplies
- LC‑MS vials and low‑binding sample tubes (documentation/compatibility purposes)
- Analytical‑grade solvents and reagents for LC‑MS workflows (for laboratory documentation only)
- Solid‑phase extraction cartridges and ion‑exchange supplies (for analytical method replication documentation)
- Laboratory consumables for cell culture assays (plates, pipette tips; documentation only)
Research organization supplies: Common tools used for research documentation workflows may include lab notebooks, label makers, sample storage boxes, inventory stickers, and temperature log sheets.
Paid-link disclosure: Peptide Bio Index may earn a commission from qualifying purchases. As an Amazon Associate I earn from qualifying purchases.
Batch and inventory labeling
Phomemo M110 Label and Barcode Printer
A compact thermal label printer for inventory identifiers, storage-box labels, batch references, and document-folder organization.
Label-printer refill
Phomemo M110 White Replacement Labels
White 1.57 × 0.78 inch replacement labels for compatible Phomemo printers. Confirm printer and label-size compatibility before ordering.
Product listings, specifications, and availability can change. Review the current Amazon listing and manufacturer instructions before ordering. These links are for research organization and compatible surface/equipment-cleaning workflows, not personal-use guidance.
Research Supply Note: For research-use-only sourcing, review current SourcePoint Research inventory and batch documentation at SourcePointResearch.com. Peptide Bio Index is affiliated with SourcePoint Research.
Sources and references
- [S1] Rahman OF, Lee SJ, Seeds WA. Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions.. Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews. 2026. PMID: 41490200. DOI: 10.5435/JAAOSGlobal-D-25-00236
- [S2] Mayfield CK, Bolia IK, Feingold CL, Lin EH, Liu JN, Rick Hatch GF. Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians.. The American journal of sports medicine. 2026. PMID: 41476424. DOI: 10.1177/03635465251357593
- [S3] Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.. Sports medicine (Auckland, N.Z.). 2026. PMID: 41966639. DOI: 10.1007/s40279-026-02437-0
- [S4] Rahaman KA, Muresan AR, Min H, Son J, Han HS, Kang MJ. Simultaneous quantification of TB-500 and its metabolites in in-vitro experiments and rats by UHPLC-Q-Exactive orbitrap MS/MS and their screening by wound healing activities in-vitro.. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2024. PMID: 38382158. DOI: 10.1016/j.jchromb.2024.124033
- [S5] Mavrych V, Shypilova I, Bolgova O. Therapeutic peptides in gerontology: mechanisms and applications for healthy aging.. Frontiers in aging. 2026. PMID: 42021992. DOI: 10.3389/fragi.2026.1790247
- [S6] Thevis M, Schänzer W. Analytical approaches for the detection of emerging therapeutics and non-approved drugs in human doping controls.. Journal of pharmaceutical and biomedical analysis. 2014. PMID: 24906629. DOI: 10.1016/j.jpba.2014.05.020
- [S7] Biçer O, Adanir O, Güleryüz Y, Balci EC, Dinçel YM, Yenigün MY. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study.. Joint diseases and related surgery. 2026. PMID: 42542926. DOI: 10.52312/jdrs.2026.2951
- [S8] Ho EN, Kwok WH, Lau MY, Wong AS, Wan TS, Lam KK. Doping control analysis of TB-500, a synthetic version of an active region of thymosin β₄, in equine urine and plasma by liquid chromatography-mass spectrometry.. Journal of chromatography. A. 2012. PMID: 23084823. DOI: 10.1016/j.chroma.2012.09.043
Peptide Bio Index is affiliated with SourcePoint Research. Articles may link to SourcePointResearch.com and third-party affiliate products. As an Amazon Associate, Peptide Bio Index earns from qualifying purchases. Content is educational and research-literature focused only and is not medical advice, dosing guidance, or a personal-use recommendation.